Emerging Markets Segment — Net Sales
Viatris Emerging Markets Segment — Net Sales decreased by 5.0% to $537.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 2.7%, from $523.10M to $537.40M. Over 4 years (FY 2021 to FY 2025), Emerging Markets Segment — Net Sales shows a downward trend with a -8.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful market penetration or rising demand in developing regions, while a decrease may signal competitive pressure or macroeconomic headwinds in those territories.
Detailed definition
This metric represents the total revenue generated from the sale of pharmaceutical products within the company's designa...
Peer comparison
Commonly reported by global pharmaceutical companies as 'International' or 'Emerging Markets' revenue segments.
vtrs_segment_emerging_markets_segment_net_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $870.00M | $792.50M | $727.50M | $705.20M | $650.90M | $678.90M | $602.00M | $641.90M | $648.10M | $642.50M | $630.40M | $628.80M | $582.30M | $535.30M | $514.00M | $523.10M | $556.90M | $571.80M | $565.80M | $537.40M |
| QoQ Change | — | -8.9% | -8.2% | -3.1% | -7.7% | +4.3% | -11.3% | +6.6% | +1.0% | -0.9% | -1.9% | -0.3% | -7.4% | -8.1% | -4.0% | +1.8% | +6.5% | +2.7% | -1.0% | -5.0% |
| YoY Change | — | — | — | — | -25.2% | -14.3% | -17.3% | -9.0% | -0.4% | -5.4% | +4.7% | -2.0% | -10.2% | -16.7% | -18.5% | -16.8% | -4.4% | +6.8% | +10.1% | +2.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's emerging markets segment — net sales?
- Viatris (VTRS) reported emerging markets segment — net sales of $537.40M in Q1 2026.
- How has Viatris's emerging markets segment — net sales changed year-over-year?
- Viatris's emerging markets segment — net sales increased by 2.7% year-over-year, from $523.10M to $537.40M.
- What is the long-term trend for Viatris's emerging markets segment — net sales?
- Over 4 years (2021 to 2025), Viatris's emerging markets segment — net sales has grown at a -8.4% compound annual growth rate (CAGR), from $3.14B to $2.22B.
- What does emerging markets segment — net sales mean?
- Total revenue earned from pharmaceutical sales in emerging market regions.